Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | TP53 R181E |
Therapy | Doxorubicin + SAR405838 |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 R181E | Advanced Solid Tumor | sensitive | Doxorubicin + SAR405838 | Preclinical - Cell culture | Actionable | In a preclinical study, SAR405838 and Adriamycin (doxorubicin) combination treatment induced cytotoxicity in transformed mouse cells expressing TP53 R181E in culture (PMID: 31483066). | 31483066 |
PubMed Id | Reference Title | Details |
---|---|---|
(31483066) | Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses. | Full reference... |